BRIEF-Thrombogenics Initiates Phase 2 Clinical Study For Treatment Of Diabetic Macular Edema

* THROMBOGENICS INITIATES PHASE 2 CLINICAL STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB) FOR TREATMENT OF DIABETIC MACULAR EDEMA (DME)

from Reuters: Company News https://ift.tt/2r18UBI
via IFTTT